References
- 1. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990;20(2):129-34.10.1016/0165-0327(90)90126-S
- 2. Chandraiah S, Levenson JL, Collins JB. Sexual dysfunction, social maladjustment, and psychiatric disorders in women seeking treatment in a premenstrual syndrome clinic. Int J Psychiatry Med. 1991;21(2):189-204.10.2190/A4JM-PGR9-35PH-4WCW
- 3. Stout AL, Steege JF, Blazer DG, George LK. Comparison of lifetime psychiatric diagnoses in Premenstrual Syndrome Clinic and community samples. J Nerv Ment Dis. 1986;174(9):517-22.10.1097/00005053-198609000-00002
- 4. Harrison WM, Endicott J, Nee J, Glick H, Rabkin JG. Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics. 1989;30(4):405-11.10.1016/S0033-3182(89)72246-5
- 5. Fava M, Pedrazzi F, Guaraldi GP, Romano J, Genazzani AR, Facchinett F. Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder. J Anx Disord. 1992;6(4):325-35.10.1016/0887-6185(92)90004-Q
- 6. Cameron OG, Kuttesch D, McPhee K, Curtis GC. Menstrual fluctuation in the symptoms of panic anxiety. J Affect Disord. 1988;15:169-74.10.1016/0165-0327(88)90086-9
- 7. Cook BL, Noyes R, Garvey MJ, Beach V, Sobotka J, Chaudhry D. Anxiety and the menstrual cycle in panic disorder. J Affect Disord. 1990;19(3):221-6.10.1016/0165-0327(90)90095-P
- 8. Stein MB, Schmidt PJ, Rubinow DR, Uhde TW. Panic disorder and the menstrual cycle: panic disorder patients, healthy control subjects, and patients with premenstrual syndrome. Am J Psychiatry. 1989;146(10):1299-303.10.1176/ajp.146.10.1299
- 9. Kaspi S, Otto MW, Pollack MH, Eppinger S, Rosenbaum JF. Premenstrual exacerbation of symptoms in women with panic disorder. J Anx Disord. 1994;8(2):131-8.10.1016/0887-6185(94)90011-6
- 10. Vickers K, McNally RJ. Is premenstrual dysphoria a variant of panic disorder? A review. Clin Psychol Rev. 2004;24(8):933-56.10.1016/S0272-7358(04)00102-3
- 11. Le Melledo JM, Bradwejn J, Koszycki D, Bichet D. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry. 1995;52(7):605-6.10.1001/archpsyc.1995.03950190087012
- 12. Le Melledo J, Van Driel M, Coupland NJ, Lott P, Jhangri GS. Response to flumazenil in women with premenstrual dysphoric disorder. Am J Psychiatry. 2000;157(5):821-3.10.1176/appi.ajp.157.5.821
- 13. Adewuya AO, Loto OM, Adewumi TA. Premenstrual dysphoric disorder amongst Nigerian university students: prevalence, comorbid conditions, and correlates. Arch Womens Ment Health. 2008;11(1):13-8.10.1007/s00737-008-0213-4
- 14. Schwartz GE, Goetz RR, Klein DF, Endicott J, Gorman JM. Tidal volume of respiration and “sighing” as indicators of breathing irregularities in panic disorder patients. Anxiety. 1996;2(3):145-8.10.1002/(SICI)1522-7154(1996)2:3<145::AID-ANXI6>3.0.CO;2-O
- 15. Harrison WM, Sandberg D, Gorman JM, Fyer M, Nee J, Uy J, et al. Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. Psychiatry Res. 1989;27(2):183-92.10.1016/0165-1781(89)90133-9
- 16. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (M.i.N.i.): the development and validation of structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22-33.
- 17. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2003;6(3):203-9.10.1007/s00737-003-0018-4
- 18. Matsumoto TH, Asakura T, Hayashi T. Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder. Gynecol Endocrinol. 2013;29(1):67-73.10.3109/09513590.2012.705383
- 19. Miyaoka Y, Akimoto Y, Ueda K, Ujiie Y, Kametani M, Uchiide Y, et al. Fulfillment of the premenstrual dysphoric disorder criteria confirmed using a self-rating questionnaire among Japanese women with depressive disorders. Biopsychosoc Med. 2011 2;5:5.10.1186/1751-0759-5-5
- 20. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord. 2002;70(2):125-32.10.1016/S0165-0327(01)00458-X
- 21. Sehlo MG, Youssef UM, Mahdy RS, El-Gohari H. Prevalence and symptoms of premenstrual dysphoric disorder in a sample of psychiatric patients at Zagazig University Hospitals. Egypt J Psychiatry. 2018;39(2):83-8.10.4103/ejpsy.ejpsy_36_17
- 22. Halbreich U, O’Brien PM, Eriksson E, Backstrom T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006;20(7):523-47.10.2165/00023210-200620070-00001
- 23. Kim DR, Gyulai L, Freeman EW, Morrison ME, Baldassano C, Dube B. Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch Womens Ment Health. 2004;7(1):37-47.10.1007/s00737-003-0027-3
- 24. Breaux C, Hartlage S, Gehlert S. Relationships of premenstrual dysphoric disorder to major depression and anxiety disorders: a re-examination. J Psychosom Obstet Gynecol. 2000;21(1):17-24.10.3109/01674820009075604
- 25. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997;278(12):983-8.10.1001/jama.1997.03550120043031
- 26. Landen M, Nissbrandt H, Allgulander C, Sörvik K, Ysander C, Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology. 2007;32(1):153-61.10.1038/sj.npp.1301216
- 27. Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRis. J Womens Health (Larchmt). 2006;15(1):57-69.10.1089/jwh.2006.15.57
- 28. Steiner M, Romano SJ, Babcock S, Dillon J, Shuler C, Berger C, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG. 2001;108(5):462-8.10.1111/j.1471-0528.2001.00120.x
- 29. Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome : asystematic review. The Lancet. 2000;356(9236):1131-6.10.1016/S0140-6736(00)02754-9
- 30. O’Brien PM, BackstromT, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14(1):13-21.10.1007/s00737-010-0201-3413492821225438
- 31. Walsh S, Ismaili E, Naheed B, O’Brien S. Diagnosis, pathophysiology and management of premenstrual syndrome. Obstet Gynaecol. 2015;17:99-104.10.1111/tog.12180
- 32. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;7(6):CD001396.10.1002/14651858.CD001396.pub3707341723744611